

GREATBATCH, INC.
Form 8-K
November 30, 2015

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event Reported): November 30, 2015

GREATBATCH, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation)	1-16137 (Commission File Number)	16-1531026 (I.R.S. Employer Identification Number)
2595 Dallas Parkway, Suite 310, Frisco, Texas (Address of Principal Executive Offices)	75034 (Zip Code)	75034 (Zip Code)
Registrant's telephone number, including area code: (716) 759-5600		

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On November 30, 2015, Greatbatch, Inc. (the "Company") issued a press release announcing that it has received Premarket Approval (PMA) from the United States Food & Drug Administration for its Algovita spinal cord stimulation system for the treatment of chronic pain of the trunk and limbs. Receipt of this approval reflects the Company's strategic evolution of its product offerings to include the development of complete medical devices.

A copy of the press release announcing the receipt of the approval is attached as Exhibit 99.1 to this report.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release dated November 30, 2015

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 30, 2015

GREATBATCH, INC.

By: /s/ MICHAEL DINKINS
Michael Dinkins
Executive Vice President and
Chief Financial Officer